Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas.
The diagnosis of follicular dendritic cell (FDC) sarcoma can be challenging because of its morphologic overlaps with many other spindle cell neoplasms and, therefore, new phenotypic markers will be helpful in its differential diagnosis. Podoplanin is a mucin-type transmembrane glycoprotein that has recently been detected in reactive FDCs. In this study, we investigated the expression patterns of podoplanin using a new mouse monoclonal antibody D2-40, and compared them with CD21, a well-established FDC marker, in a comprehensive panel of cases. The panel included 4 FDC sarcomas, 38 spindle cell neoplasms of other types, 25 reactive lymphoid hyperplasia, and 117 lymphoid and 5 myeloid malignant hematopoietic neoplasms. Our study revealed that D2-40 strongly stained 3 of 4 FDC sarcomas. In contrast, D2-40 stained only 2/38 other spindle cell neoplasms tested. Furthermore, we observed that D2-40 highlighted more FDC meshworks than CD21 in Castleman's disease, follicular lymphoma, nodular lymphocyte predominance Hodgkin lymphoma, and residual reactive germinal centers in a variety of lymphoma types. D2-40 and CD21 stained an equal number of cases of reactive lymphoid hyperplasia, progressively transformed germinal centers and angioimmunoblastic T-cell lymphoma. No expression of podoplanin was detected in normal or neoplastic lymphoid and myeloid cells. We conclude that podoplanin (D2-40) is a sensitive and specific FDC marker, which is superior or equal to CD21 in evaluating both reactive and neoplastic FDCs. In addition, our results suggest that podoplanin (D2-40) can be used to support the diagnosis of FDC sarcoma.
Xie
Qingmei
Q
Department of Pathology, Creighton University Medical Center, Omaha, NE, USA. qingmeixie@creighton.edu
Chen
Lugen
L
Fu
Kai
K
Harter
Josephine
J
Young
Ken H
KH
Sunkara
Jaya
J
Novak
Deborah
D
Villanueva-Siles
Esperanza
E
Ratech
Howard
H
Mod Pathol. 2002 Apr;15(4):434-40
11950918
Immunology. 2005 Jan;114(1):2-10
15606789
Histochem J. 1995 Mar;27(3):167-83
7797422
Cancer. 1997 Jan 15;79(2):294-313
9010103
Histopathology. 2002 Jul;41(1):1-29
12121233
J Immunol. 1998 Feb 1;160(3):1078-84
9570519
Am J Pathol. 1986 Mar;122(3):562-72
2420185
J Immunol. 2006 Jul 1;177(1):280-9
16785523
Am J Clin Pathol. 2007 Nov;128(5):776-82
17951199
Adv Anat Pathol. 2006 Mar;13(2):83-8
16670463
EMBO J. 2003 Jul 15;22(14):3546-56
12853470
Am J Surg Pathol. 1998 Sep;22(9):1048-58
9737236
Am J Surg Pathol. 2001 Jun;25(6):721-31
11395549
Mod Pathol. 2002 Jan;15(1):50-8
11796841
Am J Pathol. 2005 Mar;166(3):913-21
15743802
Am J Surg Pathol. 2004 Aug;28(8):988-98
15252304
Br J Cancer. 1999 May;80(3-4):569-78
10408868
Semin Diagn Pathol. 1998 May;15(2):144-54
9606805
Am J Pathol. 1999 Feb;154(2):385-94
10027397
Mod Pathol. 2005 Feb;18(2):260-6
15467709
Virchows Arch. 2006 Aug;449(2):148-58
16758173
Am J Surg Pathol. 1996 Aug;20(8):944-55
8712294
Semin Immunol. 2002 Aug;14(4):251-7
12163300